Skip to main content
SpringerLink
Log in

Therapy of Spondyloarthritides

  • Chapter
Molecular Mechanisms of Spondyloarthropathies

Part of the book series: Advances in Experimental Medicine and Biology ((volume 649))

Abstract

Ankylosing spondylitis (AS) is the major subtype and a major outcome of an interrelated group of rheumatic diseases now named as spondyloarthritides (SpA). The most important clinical features of this group are inflammatory back pain (IBP), asymmetric peripheral oligoarthritis, predominantly of the lower limbs, enthesitis and specific organ involvement such as anterior uveitis, psoriasis and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. For clinical purposes, five subgroups are differentiated: AS, psoriatic SpA (PsSpA), reactive SpA (ReSpA), SpA associated with inflammatory bowel disease (SpAIBD) and undifferentiated SpA (uSpA). The SpA are genetically linked, the strongest known contributing factor is the MHC class I molecule HLA B27, ARTS-7, and IL-23R, others still remain to be identified.

Most frequently and characteristically, AS starts in the sacroiliac joints at a mean age of 26 years affecting men only slightly more frequent than women. In about 80% of the patients the disease spreads to the spine where all three segments are affected, most frequently the thoracic spine. Osteodestructive structural changes such as erosions occur less frequently than osteoproliferative changes which are pathognomonic for AS being clinically impressive by their appearance as syndesmophytes and ankylosis.

Established classification criteria for AS and SpA perform less well in early disease stages. This partly contributes to the delay of diagnosis which is in the range of 5–10 years—mainly due the high frequency of back pain in the population. Major factors to improve the rate of AS patients diagnosed early are HLA B27 and imaging of the sacroiliac joints.

International recommendations for the management of AS have been published. The conventional treatment is mainly based on NSAIDs, patients with peripheral arthritis may be treated with sulfasalazine and patients with persistently active disease benefit from therapy with anti-TNF agents. Physiotherapy is of major importance in the general approach to patients with AS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braun J, Sieper J. Ankylosing spondylitis. The Lancet 2007; 369:1379–1390.

    Article  Google Scholar 

  2. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum Dis 2006; 65(4):442–52.

    Article  PubMed  CAS  Google Scholar 

  3. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65(3):316–20.

    Article  PubMed  CAS  Google Scholar 

  4. Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2007; 21(4):699–712.

    Article  PubMed  Google Scholar 

  5. van der Heijde D, Bellamy N, Calin A et al. Assessments in ankylosing spondylitis working group. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997; 24:2225–29.

    PubMed  Google Scholar 

  6. van der Heijde D, Calin A, Dougados M et al. ASAS working group. Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS group. J Rheumatol 1999; 26:951–54.

    PubMed  Google Scholar 

  7. Garrett S, Jenkinson T, Kennedy G et al. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index (BASDAI). J Rheumatol 1994; 1:2286–91.

    Google Scholar 

  8. Calin A, Nakache J-P, Gueguen A et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38:878–82.

    Article  PubMed  CAS  Google Scholar 

  9. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 1994; 21:2281–85.

    PubMed  CAS  Google Scholar 

  10. Spoorenberg A, van der Heijde D, de Klerk E et al. A comparative study of the usefulness of the bath ankylosing spondylitis functional index and the dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26:961–65.

    PubMed  CAS  Google Scholar 

  11. Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology 2005; 44:577–86.

    Article  PubMed  CAS  Google Scholar 

  12. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127–32.

    Article  PubMed  CAS  Google Scholar 

  13. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187–93.

    Article  PubMed  CAS  Google Scholar 

  14. Dagfinrud H, Vollestad NK, Loge JH et al. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005; 53:5–11.

    Article  PubMed  Google Scholar 

  15. van Tubergen A, Coenen J, Landewé R et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002; 47:8–16.

    Article  PubMed  Google Scholar 

  16. Jenkinson TR, Mallorie PA, Whitelock HC et al. Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 1994; 21(9):1694–98.

    PubMed  CAS  Google Scholar 

  17. Taylor HG, Wardle T, Beswich EJ et al. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol 1991; 30:330–35.

    Article  PubMed  CAS  Google Scholar 

  18. Creemers MCW, Franssen MJAM, van’ t Hof MA et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64:127–29.

    Article  PubMed  CAS  Google Scholar 

  19. Calin A, Mackay K, Santos H et al. A new dimension to outcome: application of the bath ankylosing spondylitis radiology index. J Rheumatol 1999; 26:988–92.

    PubMed  CAS  Google Scholar 

  20. Wanders AJ, Landewe RB, Spoorenberg A et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004; 50(8):2622–32.

    Article  PubMed  Google Scholar 

  21. Baraliakos X, Landewe R, Hermann KG et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64:730–34.

    Article  PubMed  CAS  Google Scholar 

  22. Braun J, Baraliakos X, Golder W et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004; 63:1046–55.

    Article  PubMed  CAS  Google Scholar 

  23. Braun J, Baraliakos X, golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48:1126–36.

    Article  PubMed  CAS  Google Scholar 

  24. Heuft-Dorenbosch L, Landewe R, Weijers R et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006; 65(6):804–8.

    Article  PubMed  CAS  Google Scholar 

  25. Balint PV, Kane D, Wilson H et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61:905–10.

    Article  PubMed  CAS  Google Scholar 

  26. D’Agostino MA, Said-Nahal R, Hacquard-Bouder C et al. Assessment of peripheral enthesitis in the spondyloarthropathies by ultrasonography combined with power doppler: a cross-sectional study. Arthritis Rheum 2003; 48:523–33.

    Article  PubMed  Google Scholar 

  27. Spoorenberg A, van der Heijde D, de Klerk E et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26:980–84.

    PubMed  CAS  Google Scholar 

  28. Anderson JJ, Baron G, van der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876–86.

    Article  PubMed  CAS  Google Scholar 

  29. Stone MA, Inman RD, Wright JG et al. Validation exercise of the ankylosing spondylitis assessment study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004; 51:316–20.

    Article  PubMed  CAS  Google Scholar 

  30. Brandt J, Listing J, Sieper J et al. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63:1438–44.

    Article  PubMed  CAS  Google Scholar 

  31. Dougados M, Dijkmans B, Khan M et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61(Suppl 3):iii40–50.

    PubMed  CAS  Google Scholar 

  32. Kraag G, Stokes B, Groh J et al. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—a randomized controlled trial. J Rheumatol 1990; 17(2):228–33.

    PubMed  CAS  Google Scholar 

  33. van Tubergen A, Landewe R, van der Heijde D et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45(5):430–8.

    Article  PubMed  Google Scholar 

  34. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 2005 32(10):1899–906.

    PubMed  Google Scholar 

  35. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990; 57(2):85–9.

    PubMed  CAS  Google Scholar 

  36. Dougados M, Behier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44(1):180–5.

    Article  PubMed  CAS  Google Scholar 

  37. Wanders A, Heijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52(6):1756–65.

    Article  PubMed  CAS  Google Scholar 

  38. Ward MM, Kuzis S. Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum 2002; 47(3):234–41.

    Article  PubMed  CAS  Google Scholar 

  39. Zochling J, Bohl-Buhler MH, Baraliakos X et al. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol 2006; [Epub ahead of print].

    Google Scholar 

  40. Dougados M, vam der Linden S, Leirisalo-Repo M et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38(5):618–27.

    Article  PubMed  CAS  Google Scholar 

  41. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005 (2):CD004800.

    Google Scholar 

  42. Braun J, Zochling J, Baraliakos X et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. Ann Rheum Dis 2006; 65(9):1147–53.

    Article  PubMed  CAS  Google Scholar 

  43. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004(3):CD004524.

    PubMed  Google Scholar 

  44. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31(8):1568–74.

    PubMed  CAS  Google Scholar 

  45. Haibel H, Brandt HC, Song IH et al. Results of an open label pilot study with 20 mg methotrexate parenterally for the treatment of active anklyosing spondylitis. Ann Rheum Dis 2006; in press.

    Google Scholar 

  46. Haibel H, Rudwaleit M, Braun J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64(1):124–6.

    Article  PubMed  CAS  Google Scholar 

  47. Van Denderen JC, Van der Paardt M, Nurmohamed MT et al. Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64:1761–1764.

    Article  PubMed  Google Scholar 

  48. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50(6):1939–50.

    Article  PubMed  CAS  Google Scholar 

  49. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46(3):766–73.

    Article  PubMed  CAS  Google Scholar 

  50. Haibel H, Brandt J, Rudwaleit M et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 2003; 42(8):1018–20.

    Article  CAS  Google Scholar 

  51. Huang F, Gu J, Zhao W et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47(3):249–54.

    Article  PubMed  CAS  Google Scholar 

  52. Heiberg MS, Nordvag BY, Mikkelsen K et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52(8):2506–12.

    Article  PubMed  CAS  Google Scholar 

  53. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2):582–91.

    Article  PubMed  Google Scholar 

  54. Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11):3230–6.

    Article  PubMed  CAS  Google Scholar 

  55. Calin A, Dijkmans BA, Emery P et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63(12):1594–600.

    Article  PubMed  CAS  Google Scholar 

  56. van der Heijde D, Kivitz A, Schiff M et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: The ATLAS Trial. Arthritis Rheum 2006; 54:2136–46.

    Article  PubMed  Google Scholar 

  57. Braun J, Landewe R, Hermann KG et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54(5):1646–52.

    Article  PubMed  CAS  Google Scholar 

  58. Baraliakos X, Davis J, Tsuji W. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005; 52:1216–23.

    Article  PubMed  CAS  Google Scholar 

  59. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis—clinical and magnetic resonance imaging results of a fifty-two week open label trial. Arthritis Rheum 2006; 54:678–81.

    Article  PubMed  CAS  Google Scholar 

  60. Sieper J, Baraliakos X, Listing J et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005; 44:1525–30.

    Article  CAS  Google Scholar 

  61. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active anklyosing spondylitis after 2 years of therapy with etanercept—clinical and magnetic resonance imaging data. Arthritis Res Ther 2005; 7(3):113.

    Article  Google Scholar 

  62. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005; 44(5):670–6.

    Article  CAS  Google Scholar 

  63. Davis JC, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2007; [Epub ahead of print].

    Google Scholar 

  64. Braun J, Baraliakos X, Listing J et al. Persistent clinical efficacy and safety of anti-TNF{alpha{ therapy with infliximab in patients with ankylosing spondylitis over 5 years—evidence for different types of response. Ann Rheum Dis 2007; [Epub ahead of print].

    Google Scholar 

  65. Baraliakos X, Listing J, Brandt J et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7(3):R439–44.

    Article  PubMed  CAS  Google Scholar 

  66. Brandt J, Kariouzov A, Listing J et al. Six months results of a German double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003; 48(6):1667–75.

    Article  PubMed  CAS  Google Scholar 

  67. Baraliakos X, Listing J, Rudwaleit M et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the TNF-α antibody infliximab. Ann Rheum Dis 2005; 64(10):1462–6.

    Article  PubMed  CAS  Google Scholar 

  68. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology (Oxford) 2007; [Epub ahead of print].

    Google Scholar 

  69. Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62:347–49.

    Article  PubMed  CAS  Google Scholar 

  70. Brandt J, Haibel H, Reddig J et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 29(1):118–22.

    PubMed  CAS  Google Scholar 

  71. Brandt J, Khariouzov A, Listing J et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31(3):531–8.

    PubMed  CAS  Google Scholar 

  72. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152(5):954–60.

    Article  PubMed  CAS  Google Scholar 

  73. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004; 50(7):2264–72.

    Article  PubMed  CAS  Google Scholar 

  74. Mease P, Gladman D, Ritchlin C et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004; 50:4097.

    Article  Google Scholar 

  75. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; [Epub ahead of print].

    Google Scholar 

  76. Marzo-Ortega H, McGonagle D, O’Connor P et al. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62(1):74–6.

    Article  PubMed  CAS  Google Scholar 

  77. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57(4):639–47.

    Article  PubMed  CAS  Google Scholar 

  78. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121(5):1088–94.

    Article  PubMed  CAS  Google Scholar 

  79. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359(9317):1541–9.

    Article  PubMed  CAS  Google Scholar 

  80. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23):2462–76.

    Article  PubMed  CAS  Google Scholar 

  81. Braun J, Baraliakos X, Listing J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52(8):2447–51.

    Article  PubMed  CAS  Google Scholar 

  82. Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65(12):1631–4. Epub 2006.

    Article  PubMed  CAS  Google Scholar 

  83. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56(10):3248–52.

    Article  PubMed  CAS  Google Scholar 

  84. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-tnf agents in patients with ankylosing spondylitis. Ann Rheum Dis 2005; [Epub ahead of print].

    Google Scholar 

  85. Rudwaleit M, Listing J, Brandt J et al. Prediction of a major clinical-response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63(6):665–70.

    Article  PubMed  CAS  Google Scholar 

  86. Tan AL, Marzo-Ortega H, O’Connor P et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63(9):1041–5.

    Article  PubMed  CAS  Google Scholar 

  87. Haibel H, Rudwaleit M, Listing J et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64(2):296–8.

    Article  PubMed  CAS  Google Scholar 

  88. Kobelt G, Andlin-Sobocki P, Brophy S et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004; 43(9):1158–66.

    Article  CAS  Google Scholar 

  89. van der Heijde D, Han C, Devlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006; 55(4):569–574.

    Article  PubMed  Google Scholar 

  90. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361–8.

    Article  PubMed  Google Scholar 

  91. Haibel H, Rudwaleit M, Listing J et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroilitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58(7):1981–1991.

    Article  PubMed  CAS  Google Scholar 

  92. van Tubergen A, van der Heijde D, Anderson J et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis. 2003; 62(3):215–221.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652, Herne, Germany

    Jürgen Braun

Authors
  1. Jürgen Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital Universitario Central de Asturias, Oviedo, Spain

    Carlos López-Larrea PhD  & Roberto Díaz-Peña BSc  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Braun, J. (2009). Therapy of Spondyloarthritides. In: López-Larrea, C., Díaz-Peña, R. (eds) Molecular Mechanisms of Spondyloarthropathies. Advances in Experimental Medicine and Biology, vol 649. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0298-6_10

Download citation

Publish with us

Policies and ethics

Search

Navigation